ATP as a death factor: purinergic signaling in renal epithelial-fibroblast cross talk

Abstract

Editorial FocusATP as a death factor: purinergic signaling in renal epithelial-fibroblast cross talkAbolfazl Zarjou, and Anupam AgarwalAbolfazl ZarjouDepartment of Medicine, Division of Nephrology, Nephrology Research and Training Center, University of Alabama at Birmingham, and Department of Veterans Affairs Medical Center, Birmingham, Alabama, and Anupam AgarwalDepartment of Medicine, Division of Nephrology, Nephrology Research and Training Center, University of Alabama at Birmingham, and Department of Veterans Affairs Medical Center, Birmingham, AlabamaPublished Online:01 Jan 2011https://doi.org/10.1152/ajprenal.00593.2010This is the final version - click for previous versionMoreSectionsPDF (39 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInEmailWeChat peritubular fibroblasts are a major fraction of interstitial cells in the kidney that produce erythropoietin. In an issue of the American Journal of Physiology-Renal Physiology, Ponnusamy and colleagues (14) have explored the mechanism linking renal tubular epithelial cell death and injury to peritubular fibroblasts. The results of this work provide new insights into the mechanisms underlying the progression of acute kidney injury to renal fibrosis in chronic kidney disease.Evolution has made it possible for different organs and cells to have a meticulously orchestrated way of communication. Such processes are vital to maintain homeostasis, stimulate adaptation, and induce an appropriate response to injury. This cross talk embraces various systems, including cytokines, receptors, ion flows, signal transduction pathways, and others. One such way of interaction is via the family of purinergic “P” receptors that are classified into P1 and P2 according to their response to adenosine or ATP, respectively (1, 2). Further analysis describes P2X as ligand-gated ion channels and P2Y as G protein-coupled receptors (1, 2, 16). P2X receptors open in response to the binding of extracellular ATP. In vertebrates, there are seven distinct genes that encode P2X receptor subunits (P2X1–P2X7) sharing ∼50% homology in amino acid sequence (19). Recent evidence suggests that P2X receptors are widely distributed among tissues including neurons, hematopoietic cells, epithelium, bone, and muscle (11, 13, 19).One of the intriguing members of this family is the P2X7 receptor, which is somewhat unusual among other members in that its persistent activation by high levels of extracellular ATP induces the formation of a reversible plasma membrane pore permeable to hydrophilic solutes up to 900 Da (18, 19). This implies that apart from activating a diverse array of cellular pathways, including activation of phospholipase D, phospholipase A2, and mitogen-activated protein kinases, it could also mediate cell permeabilization to an extent that may lead to cell death. Other unique traits of these receptors are their inability to form functional heteromers with other members of the P2X family and their low affinity for ATP that requires concentrations up to 100 μm for activation (11, 19). Under physiological circumstances the ATP-sensitive P2X7 receptors are predominately present on cells of immunological origin including peripheral macrophages and glial cells in the central nervous system (3, 4). Accumulating evidence suggests that these receptors are critical mediators of cell growth, apoptosis, and necrosis, and their activation is known to have proinflammatory effects (3). Taken together, these observations and recent advances in understanding P2X7 receptor signaling pathways have led to promising avenues that are exploring the potential of inhibiting this receptor in inflammatory and neurodegenerative diseases (15, 20).Although it has been shown that P2X7 receptors are expressed during kidney development, its presence in the renal parenchyma is very limited under normal conditions (9, 19). However, studies have shown that this receptor is upregulated following injury, and its induction has been documented in animal models of glomerulonephritis and diabetic kidney disease in various cell types, including podocytes, mesangial cells, and proximal tubular cells. More importantly, human kidney biopsies from patients with lupus nephritis also display upregulation of P2X7 receptors in glomeruli and proximal tubules (10, 22, 23).In an issue of the journal, Ponnusamy and colleagues (14) have explored the mechanism linking renal tubular epithelial cell death and injury to renal interstitial peritubular fibroblasts and provide novel insights. Peritubular fibroblasts are critical interstitial cells in the kidney that produce erythropoietin (12). These cells also mediate extracellular matrix expansion following injury to maintain a careful equilibrium between repair and exaggerated fibrosis that could potentially progress into chronic kidney disease (8). Using an in vitro system, they demonstrate that the cell supernatant from damaged renal proximal tubular epithelial cells and not the cell debris is responsible to induce death of renal peritubular fibroblasts. These damaging effects were identified to be due to release of ATP as the “pro-death factor.” They further demonstrate that these effects are mediated through P2X receptors, specifically P2X7, using multiple complementary approaches with chemical inhibitors, small interference RNA knockdown, and overexpression of P2X7. The findings in this work are consistent with recent reports that have demonstrated an important role for P2X7 receptors in the context of glomerulonephritis and suggested that deficiency of this receptor was associated with significant renoprotection (21). Another recent study reported that the tubulointerstitial damage following unilateral ureteral obstruction was attenuated in the P2X−/− mice (7). The results of this work could provide new insights into the mechanism(s) underlying the progression of acute kidney injury (where the proximal tubule bears the brunt of injury) to renal fibrosis in chronic kidney disease.In the normal kidney, ATP is released at nanomolar concentrations from thick ascending limb and collecting duct cell lines and micromolar concentrations from proximal tubular epithelial cultures (17). However, accumulating evidence suggests that higher concentrations of ATP are released from abnormal cystic epithelial cells derived from both human and mouse polycystic kidneys (17, 24). Furthermore, it is obvious that any type of insult that can lead to cell death can generate high levels of intracellular ATP and thereby increase the extracellular ATP concentration. Such high concentrations of ATP can, in turn, activate the P2X7 receptors and cause cellular apoptosis and necrosis and may (at least in part) explain the decreased erythropoietin levels and subsequent anemia that is associated with chronic kidney disease.There has been great progress in the development of P2X7 receptor antagonists (5). Such agents have already shown impressive results in treating chronic neuropathic pain and rheumatoid arthritis (6). An imperative next step is to confirm the results of the present work in relevant in vivo models of both acute and chronic kidney disease. Once validated and tested in clinical settings, these findings could offer innovative preventive and therapeutic modalities and has the potential to impact morbidity and mortality associated with kidney injury.REFERENCES1. Burnstock G. Purinergic signalling: past, present and future. Braz J Med Biol Res 42: 3–8, 2009.Crossref | PubMed | ISI | Google Scholar2. Burnstock G , Verkhratsky A. Evolutionary origins of the purinergic signalling system. Acta Physiol (Oxf) 195: 415–447, 2009.Crossref | PubMed | ISI | Google Scholar3. Chen L , Brosnan CF. Regulation of immune response by P2X7 receptor. Crit Rev Immunol 26: 499–513, 2006.Crossref | PubMed | ISI | Google Scholar4. Collo G , Neidhart S , Kawashima E , Kosco-Vilbois M , North RA , Buell G. Tissue distribution of the P2X7 receptor. Neuropharmacology 36: 1277–1283, 1997.Crossref | PubMed | ISI | Google Scholar5. Donnelly-Roberts DL , Jarvis MF. Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol 151: 571–579, 2007.Crossref | PubMed | ISI | Google Scholar6. Gever JR , Cockayne DA , Dillon MP , Burnstock G , Ford AP. Pharmacology of P2X channels. Pflügers Arch 452: 513–537, 2006.Crossref | PubMed | ISI | Google Scholar7. Goncalves RG , Gabrich L , Rosario A , Takiya CM , Ferreira ML , Chiarini LB , Persechini PM , Coutinho-Silva R , Leite M. The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice. Kidney Int 70: 1599–1606, 2006.Crossref | PubMed | ISI | Google Scholar8. Hewitson TD. Renal tubulointerstitial fibrosis: common but never simple. Am J Physiol Renal Physiol 296: F1239–F1244, 2009.Link | ISI | Google Scholar9. Hillman KA , Burnstock G , Unwin RJ. The P2X7 ATP receptor in the kidney: a matter of life or death? Nephron Exp Nephrol 101: e24–e30, 2005.Crossref | PubMed | Google Scholar10. Huang XR , Tipping PG , Apostolopoulos J , Oettinger C , D'Souza M , Milton G , Holdsworth SR. Mechanisms of T cell-induced glomerular injury in anti-glomerular basement membrane (GBM) glomerulonephritis in rats. Clin Exp Immunol 109: 134–142, 1997.Crossref | PubMed | ISI | Google Scholar11. Jarvis MF , Khakh BS. ATP-gated P2X cation-channels. Neuropharmacology 56: 208–215, 2009.Crossref | PubMed | ISI | Google Scholar12. Kaissling B , Le Hir M. The renal cortical interstitium: morphological and functional aspects. Histochem Cell Biol 130: 247–262, 2008.Crossref | PubMed | ISI | Google Scholar13. North RA. Molecular physiology of P2X receptors. Physiol Rev 82: 1013–1067, 2002.Link | ISI | Google Scholar14. Ponnusamy M , Ma L , Gong R , Pang M , Chin YE , Zhuang S. P2X7 receptors mediate deleterious renal epithelial-fibroblast cross talk. Am J Physiol Renal Physiol. (First published September 22, 2010). doi:10.1152/ajprenal.00473.2010.Google Scholar15. Romagnoli R , Baraldi PG , Cruz-Lopez O , Lopez-Cara C , Preti D , Borea PA , Gessi S. The P2X7 receptor as a therapeutic target. Expert Opin Ther Targets 12: 647–661, 2008.Crossref | PubMed | ISI | Google Scholar16. Sawynok J. Adenosine and ATP receptors. Handb Exp Pharmacol 309–328, 2007.PubMed | Google Scholar17. Schwiebert EM , Kishore BK. Extracellular nucleotide signaling along the renal epithelium. Am J Physiol Renal Physiol 280: F945–F963, 2001.Link | ISI | Google Scholar18. Skaper SD , Debetto P , Giusti P. The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J 24: 337–345, 2010.Crossref | PubMed | ISI | Google Scholar19. Surprenant A , North RA. Signaling at purinergic P2X receptors. Annu Rev Physiol 71: 333–359, 2009.Crossref | PubMed | ISI | Google Scholar20. Takenouchi T , Sekiyama K , Sekigawa A , Fujita M , Waragai M , Sugama S , Iwamaru Y , Kitani H , Hashimoto M. P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases. Arch Immunol Ther Exp (Warsz) 58: 91–96, 2010.Crossref | PubMed | ISI | Google Scholar21. Taylor SR , Turner CM , Elliott JI , McDaid J , Hewitt R , Smith J , Pickering MC , Whitehouse DL , Cook HT , Burnstock G , Pusey CD , Unwin RJ , Tam FW. P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. J Am Soc Nephrol 20: 1275–1281, 2009.Crossref | PubMed | ISI | Google Scholar22. Turner CM , Tam FW , Lai PC , Tarzi RM , Burnstock G , Pusey CD , Cook HT , Unwin RJ. Increased expression of the pro-apoptotic ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis. Nephrol Dial Transplant 22: 386–395, 2007.Crossref | PubMed | ISI | Google Scholar23. Vonend O , Turner CM , Chan CM , Loesch A , Dell'Anna GC , Srai KS , Burnstock G , Unwin RJ. Glomerular expression of the ATP-sensitive P2X receptor in diabetic and hypertensive rat models. Kidney Int 66: 157–166, 2004.Crossref | PubMed | ISI | Google Scholar24. Wilson PD , Hovater JS , Casey CC , Fortenberry JA , Schwiebert EM. ATP release mechanisms in primary cultures of epithelia derived from the cysts of polycystic kidneys. J Am Soc Nephrol 10: 218–229, 1999.Crossref | PubMed | ISI | Google ScholarAUTHOR NOTESAddress for reprint requests and other correspondence: A. Agarwal, Div. of Nephrology, THT 647, Univ. of Alabama at Birmingham, 1900 Univ. Blvd., Birmingham, AL 35294 (e-mail: [email protected]edu). Download PDF Previous Back to Top Next FiguresReferencesRelatedInformationCited ByPurinergic Signalling: Therapeutic Developments25 September 2017 | Frontiers in Pharmacology, Vol. 8The role of adenosine receptors A2A and A2B signaling in renal fibrosisKidney International, Vol. 86, No. 4Purinergic signalling in the kidney in health and disease22 November 2013 | Purinergic Signalling, Vol. 10, No. 1 More from this issue > Volume 300Issue 1January 2011Pages F60-F61 https://doi.org/10.1152/ajprenal.00593.2010PubMed20962119History Published online 1 January 2011 Published in print 1 January 2011 Metrics